恩帕格利弗洛辛诱导的肌肉病变
1Freeman Health System, KCU-GME Consortium, Joplin, MO 64804, USA.
JCEM case reports
|November 29, 2024
概括
用于糖尿病和心力衰竭的/葡萄糖共运输体2 (SGLT2) 抑制剂可能导致药物诱导肌肉病变. 一位患者在开始使用empagliflozin后出现肌肉疼痛和肌肉虚弱,在停止治疗后消失.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- /葡萄糖共载体2 (SGLT2) 抑制剂广泛用于2型糖尿病,充血性心力衰竭 (CHF) 和慢性病.
- 虽然通常是安全的,但潜在的不良影响需要持续监测和研究.
研究的目的:
- 报告与使用SGLT2抑制剂相关的药物诱导肌痛病例.
- 为了突出一种罕见但严重的empagliflozin的副作用.
主要方法:
- 一个病例报告,一名47岁的患者患有2型糖尿病和心血管衰竭,在开始使用empagliflozin后发展为肌肉病.
- 进行了临床评估和实验室测试,包括肌氨酸激酶 (CK) 水平.
主要成果:
- 患者在开始使用empagliflozin后出现肌肉疼痛和肌肉虚弱.
- 实验室测试证实CK水平升高,表明肌肉病.
- 症状和升高的CK水平在停止使用empagliflozin时消失.
结论:
- 作为SGLT2抑制剂的empagliflozin可以导致药物诱导的肌肉病变.
- 当医生处方SGLT2抑制剂时,医生应考虑肌肉病作为潜在的不良影响,特别是在具有危险因素的患者中.
- 这一案例补充了关于SGLT2抑制剂相关肌肉病变和狂宫痛解的有限文献.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
Disorders of the Skeletal Muscle
879
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
879
Antiepileptic Drugs: Potassium Channel Activators
146
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
146
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
cAMP-dependent Protein Kinase Pathways
6.1K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.1K


